Functional implications of single nucleotide polymorphisms rs662 and rs854860 on the antioxidative activity of paraoxonase1 (PON1) in patients with rheumatoid arthritis
Background Atherosclerosis leading to cardiovascular disease (CVD) is the main cause of mortality and morbidity in patients with rheumatoid arthritis (RA). Paraoxonase1 (PON1) is the best understood member of plasma paraoxonases with anti-atherogenic properties. Patients and methods Spanish RA ( n ...
Gespeichert in:
| Veröffentlicht in: | Clinical rheumatology 2019-05, Vol.38 (5), p.1329-1337 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1337 |
|---|---|
| container_issue | 5 |
| container_start_page | 1329 |
| container_title | Clinical rheumatology |
| container_volume | 38 |
| creator | Mucientes, Arkaitz Fernández-Gutiérrez, Benjamín Herranz, Eva Rodriguez-Rodriguez, Luis Varadé, Jezabel Urcelay, Elena Lamas, José Ramón |
| description | Background
Atherosclerosis leading to cardiovascular disease (CVD) is the main cause of mortality and morbidity in patients with rheumatoid arthritis (RA). Paraoxonase1 (PON1) is the best understood member of plasma paraoxonases with anti-atherogenic properties.
Patients and methods
Spanish RA (
n
= 549) consecutively recruited from 1 single center and 477 ethnically matched healthy controls were included in a case-control study. The concentration of PON1 was evaluated by means of an enzyme-linked immunosorbent sssay (ELISA). An arylesterase/paraoxonase assay kit was used to evaluate PON1 activity. Sample genotyping was performed by using TaqMan assays-on-demand. All results were expressed as medians ± interquartile range. One-way ANOVA comparisons were done using a nonparametric Kruskall-Wallis test.
P
values under 0.05 were considered to be significant.
Results
The concentration of PON1 in the RA group was higher than in control group (
p
= 0.0003), although the differences were not significant when PON1 activities were compared between both groups. No significant differences were found related to distributions of rs662 genotypes in RA patients compared to healthy controls. Among rs854860 polymorphisms, overall genotype was widely distributed between RA patients and controls. Overall PON1 concentration in plasma was not significantly different between individuals carrying any of rs662 (
p
= 0.8501) or rs854860 (
p
= 0.2741) polymorphisms. Although PON1 levels were not associated with any of the SNPs in the study, differences appear when enzyme activities are compared for each SNP separately. CVD in RA patients correlate with increased PON1 levels and lower PON1 activity.
Conclusions
Although protective role of PON1 against oxidative damage in vivo could be related to other activities, in our study arylesterase activity was useful to identify phenotypic differences with emphasis placed on two SNPs coding for nonconservative amino acid changes in the functional protein. |
| doi_str_mv | 10.1007/s10067-018-4394-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2161065190</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2160648693</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-7a0b0b186f922f164d190f226b393cbd7e469739085d640aae87b6456cbc0d613</originalsourceid><addsrcrecordid>eNp1kcFuFSEUhonR2Gv1AdwYEjd1MXoYGAaWprFq0lgXuiYMMB2aGRiBqb1v5GPK9VZNTNwA5_Cd_0_Oj9BzAq8JQP8m15P3DRDRMCpZwx-gHWGUNVIy-RDtoO-hoUSKE_Qk5xsAaIUkj9EJhU6IruM79ONiC6b4GPSM_bLO3uhDlXEccfbhenY4bGZ2sXjr8Brn_RLTOvm8ZJwy5y3WwdaX6JjggGPAZXK1V0XuvK1at7WqBre-7A-aq0463lW77Ag--3z1ibzCPtR28S6UjL_7MuE0uW3RJXqLdSpT8sXnp-jRqOfsnt3fp-jrxbsv5x-ay6v3H8_fXjaGka40vYYBBiL4KNt2JJxZImFsWz5QSc1ge8e47KkE0VnOQGsn-oGzjpvBgOWEnqKzo-6a4rfN5aIWn42bZx1c3LJqCSfAu6pa0Zf_oDdxS3WTvyjgdSOSVoocKZNizsmNak1-0WmvCKhDjOoYo6oxqkOMiteZF_fK27A4-2fid24VaI9Arl_h2qW_1v9X_QlvG6lE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2160648693</pqid></control><display><type>article</type><title>Functional implications of single nucleotide polymorphisms rs662 and rs854860 on the antioxidative activity of paraoxonase1 (PON1) in patients with rheumatoid arthritis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Mucientes, Arkaitz ; Fernández-Gutiérrez, Benjamín ; Herranz, Eva ; Rodriguez-Rodriguez, Luis ; Varadé, Jezabel ; Urcelay, Elena ; Lamas, José Ramón</creator><creatorcontrib>Mucientes, Arkaitz ; Fernández-Gutiérrez, Benjamín ; Herranz, Eva ; Rodriguez-Rodriguez, Luis ; Varadé, Jezabel ; Urcelay, Elena ; Lamas, José Ramón</creatorcontrib><description>Background
Atherosclerosis leading to cardiovascular disease (CVD) is the main cause of mortality and morbidity in patients with rheumatoid arthritis (RA). Paraoxonase1 (PON1) is the best understood member of plasma paraoxonases with anti-atherogenic properties.
Patients and methods
Spanish RA (
n
= 549) consecutively recruited from 1 single center and 477 ethnically matched healthy controls were included in a case-control study. The concentration of PON1 was evaluated by means of an enzyme-linked immunosorbent sssay (ELISA). An arylesterase/paraoxonase assay kit was used to evaluate PON1 activity. Sample genotyping was performed by using TaqMan assays-on-demand. All results were expressed as medians ± interquartile range. One-way ANOVA comparisons were done using a nonparametric Kruskall-Wallis test.
P
values under 0.05 were considered to be significant.
Results
The concentration of PON1 in the RA group was higher than in control group (
p
= 0.0003), although the differences were not significant when PON1 activities were compared between both groups. No significant differences were found related to distributions of rs662 genotypes in RA patients compared to healthy controls. Among rs854860 polymorphisms, overall genotype was widely distributed between RA patients and controls. Overall PON1 concentration in plasma was not significantly different between individuals carrying any of rs662 (
p
= 0.8501) or rs854860 (
p
= 0.2741) polymorphisms. Although PON1 levels were not associated with any of the SNPs in the study, differences appear when enzyme activities are compared for each SNP separately. CVD in RA patients correlate with increased PON1 levels and lower PON1 activity.
Conclusions
Although protective role of PON1 against oxidative damage in vivo could be related to other activities, in our study arylesterase activity was useful to identify phenotypic differences with emphasis placed on two SNPs coding for nonconservative amino acid changes in the functional protein.</description><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-018-4394-6</identifier><identifier>PMID: 30588556</identifier><language>eng</language><publisher>London: Springer London</publisher><subject>Adult ; Aged ; Amino acid sequence ; Antioxidants - metabolism ; Arteriosclerosis ; Arthritis, Rheumatoid - complications ; Arthritis, Rheumatoid - enzymology ; Arthritis, Rheumatoid - genetics ; Aryldialkylphosphatase - genetics ; Aryldialkylphosphatase - metabolism ; Arylesterase ; Cardiovascular diseases ; Cardiovascular Diseases - enzymology ; Cardiovascular Diseases - etiology ; Cardiovascular Diseases - genetics ; Case-Control Studies ; Enzymatic activity ; Enzyme-linked immunosorbent assay ; Enzymes ; Female ; Genotype ; Genotyping ; Humans ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Morbidity ; Original Article ; Paraoxonase ; Polymorphism, Single Nucleotide ; Rheumatoid arthritis ; Rheumatology ; Single-nucleotide polymorphism ; Spain</subject><ispartof>Clinical rheumatology, 2019-05, Vol.38 (5), p.1329-1337</ispartof><rights>The Author(s) 2018</rights><rights>Clinical Rheumatology is a copyright of Springer, (2018). All Rights Reserved. © 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-7a0b0b186f922f164d190f226b393cbd7e469739085d640aae87b6456cbc0d613</citedby><cites>FETCH-LOGICAL-c415t-7a0b0b186f922f164d190f226b393cbd7e469739085d640aae87b6456cbc0d613</cites><orcidid>0000-0002-6126-8786</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10067-018-4394-6$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10067-018-4394-6$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30588556$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mucientes, Arkaitz</creatorcontrib><creatorcontrib>Fernández-Gutiérrez, Benjamín</creatorcontrib><creatorcontrib>Herranz, Eva</creatorcontrib><creatorcontrib>Rodriguez-Rodriguez, Luis</creatorcontrib><creatorcontrib>Varadé, Jezabel</creatorcontrib><creatorcontrib>Urcelay, Elena</creatorcontrib><creatorcontrib>Lamas, José Ramón</creatorcontrib><title>Functional implications of single nucleotide polymorphisms rs662 and rs854860 on the antioxidative activity of paraoxonase1 (PON1) in patients with rheumatoid arthritis</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><addtitle>Clin Rheumatol</addtitle><description>Background
Atherosclerosis leading to cardiovascular disease (CVD) is the main cause of mortality and morbidity in patients with rheumatoid arthritis (RA). Paraoxonase1 (PON1) is the best understood member of plasma paraoxonases with anti-atherogenic properties.
Patients and methods
Spanish RA (
n
= 549) consecutively recruited from 1 single center and 477 ethnically matched healthy controls were included in a case-control study. The concentration of PON1 was evaluated by means of an enzyme-linked immunosorbent sssay (ELISA). An arylesterase/paraoxonase assay kit was used to evaluate PON1 activity. Sample genotyping was performed by using TaqMan assays-on-demand. All results were expressed as medians ± interquartile range. One-way ANOVA comparisons were done using a nonparametric Kruskall-Wallis test.
P
values under 0.05 were considered to be significant.
Results
The concentration of PON1 in the RA group was higher than in control group (
p
= 0.0003), although the differences were not significant when PON1 activities were compared between both groups. No significant differences were found related to distributions of rs662 genotypes in RA patients compared to healthy controls. Among rs854860 polymorphisms, overall genotype was widely distributed between RA patients and controls. Overall PON1 concentration in plasma was not significantly different between individuals carrying any of rs662 (
p
= 0.8501) or rs854860 (
p
= 0.2741) polymorphisms. Although PON1 levels were not associated with any of the SNPs in the study, differences appear when enzyme activities are compared for each SNP separately. CVD in RA patients correlate with increased PON1 levels and lower PON1 activity.
Conclusions
Although protective role of PON1 against oxidative damage in vivo could be related to other activities, in our study arylesterase activity was useful to identify phenotypic differences with emphasis placed on two SNPs coding for nonconservative amino acid changes in the functional protein.</description><subject>Adult</subject><subject>Aged</subject><subject>Amino acid sequence</subject><subject>Antioxidants - metabolism</subject><subject>Arteriosclerosis</subject><subject>Arthritis, Rheumatoid - complications</subject><subject>Arthritis, Rheumatoid - enzymology</subject><subject>Arthritis, Rheumatoid - genetics</subject><subject>Aryldialkylphosphatase - genetics</subject><subject>Aryldialkylphosphatase - metabolism</subject><subject>Arylesterase</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - enzymology</subject><subject>Cardiovascular Diseases - etiology</subject><subject>Cardiovascular Diseases - genetics</subject><subject>Case-Control Studies</subject><subject>Enzymatic activity</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Enzymes</subject><subject>Female</subject><subject>Genotype</subject><subject>Genotyping</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>Original Article</subject><subject>Paraoxonase</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Rheumatoid arthritis</subject><subject>Rheumatology</subject><subject>Single-nucleotide polymorphism</subject><subject>Spain</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kcFuFSEUhonR2Gv1AdwYEjd1MXoYGAaWprFq0lgXuiYMMB2aGRiBqb1v5GPK9VZNTNwA5_Cd_0_Oj9BzAq8JQP8m15P3DRDRMCpZwx-gHWGUNVIy-RDtoO-hoUSKE_Qk5xsAaIUkj9EJhU6IruM79ONiC6b4GPSM_bLO3uhDlXEccfbhenY4bGZ2sXjr8Brn_RLTOvm8ZJwy5y3WwdaX6JjggGPAZXK1V0XuvK1at7WqBre-7A-aq0463lW77Ag--3z1ibzCPtR28S6UjL_7MuE0uW3RJXqLdSpT8sXnp-jRqOfsnt3fp-jrxbsv5x-ay6v3H8_fXjaGka40vYYBBiL4KNt2JJxZImFsWz5QSc1ge8e47KkE0VnOQGsn-oGzjpvBgOWEnqKzo-6a4rfN5aIWn42bZx1c3LJqCSfAu6pa0Zf_oDdxS3WTvyjgdSOSVoocKZNizsmNak1-0WmvCKhDjOoYo6oxqkOMiteZF_fK27A4-2fid24VaI9Arl_h2qW_1v9X_QlvG6lE</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Mucientes, Arkaitz</creator><creator>Fernández-Gutiérrez, Benjamín</creator><creator>Herranz, Eva</creator><creator>Rodriguez-Rodriguez, Luis</creator><creator>Varadé, Jezabel</creator><creator>Urcelay, Elena</creator><creator>Lamas, José Ramón</creator><general>Springer London</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6126-8786</orcidid></search><sort><creationdate>20190501</creationdate><title>Functional implications of single nucleotide polymorphisms rs662 and rs854860 on the antioxidative activity of paraoxonase1 (PON1) in patients with rheumatoid arthritis</title><author>Mucientes, Arkaitz ; Fernández-Gutiérrez, Benjamín ; Herranz, Eva ; Rodriguez-Rodriguez, Luis ; Varadé, Jezabel ; Urcelay, Elena ; Lamas, José Ramón</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-7a0b0b186f922f164d190f226b393cbd7e469739085d640aae87b6456cbc0d613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Amino acid sequence</topic><topic>Antioxidants - metabolism</topic><topic>Arteriosclerosis</topic><topic>Arthritis, Rheumatoid - complications</topic><topic>Arthritis, Rheumatoid - enzymology</topic><topic>Arthritis, Rheumatoid - genetics</topic><topic>Aryldialkylphosphatase - genetics</topic><topic>Aryldialkylphosphatase - metabolism</topic><topic>Arylesterase</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - enzymology</topic><topic>Cardiovascular Diseases - etiology</topic><topic>Cardiovascular Diseases - genetics</topic><topic>Case-Control Studies</topic><topic>Enzymatic activity</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Enzymes</topic><topic>Female</topic><topic>Genotype</topic><topic>Genotyping</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>Original Article</topic><topic>Paraoxonase</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Rheumatoid arthritis</topic><topic>Rheumatology</topic><topic>Single-nucleotide polymorphism</topic><topic>Spain</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mucientes, Arkaitz</creatorcontrib><creatorcontrib>Fernández-Gutiérrez, Benjamín</creatorcontrib><creatorcontrib>Herranz, Eva</creatorcontrib><creatorcontrib>Rodriguez-Rodriguez, Luis</creatorcontrib><creatorcontrib>Varadé, Jezabel</creatorcontrib><creatorcontrib>Urcelay, Elena</creatorcontrib><creatorcontrib>Lamas, José Ramón</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mucientes, Arkaitz</au><au>Fernández-Gutiérrez, Benjamín</au><au>Herranz, Eva</au><au>Rodriguez-Rodriguez, Luis</au><au>Varadé, Jezabel</au><au>Urcelay, Elena</au><au>Lamas, José Ramón</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Functional implications of single nucleotide polymorphisms rs662 and rs854860 on the antioxidative activity of paraoxonase1 (PON1) in patients with rheumatoid arthritis</atitle><jtitle>Clinical rheumatology</jtitle><stitle>Clin Rheumatol</stitle><addtitle>Clin Rheumatol</addtitle><date>2019-05-01</date><risdate>2019</risdate><volume>38</volume><issue>5</issue><spage>1329</spage><epage>1337</epage><pages>1329-1337</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><abstract>Background
Atherosclerosis leading to cardiovascular disease (CVD) is the main cause of mortality and morbidity in patients with rheumatoid arthritis (RA). Paraoxonase1 (PON1) is the best understood member of plasma paraoxonases with anti-atherogenic properties.
Patients and methods
Spanish RA (
n
= 549) consecutively recruited from 1 single center and 477 ethnically matched healthy controls were included in a case-control study. The concentration of PON1 was evaluated by means of an enzyme-linked immunosorbent sssay (ELISA). An arylesterase/paraoxonase assay kit was used to evaluate PON1 activity. Sample genotyping was performed by using TaqMan assays-on-demand. All results were expressed as medians ± interquartile range. One-way ANOVA comparisons were done using a nonparametric Kruskall-Wallis test.
P
values under 0.05 were considered to be significant.
Results
The concentration of PON1 in the RA group was higher than in control group (
p
= 0.0003), although the differences were not significant when PON1 activities were compared between both groups. No significant differences were found related to distributions of rs662 genotypes in RA patients compared to healthy controls. Among rs854860 polymorphisms, overall genotype was widely distributed between RA patients and controls. Overall PON1 concentration in plasma was not significantly different between individuals carrying any of rs662 (
p
= 0.8501) or rs854860 (
p
= 0.2741) polymorphisms. Although PON1 levels were not associated with any of the SNPs in the study, differences appear when enzyme activities are compared for each SNP separately. CVD in RA patients correlate with increased PON1 levels and lower PON1 activity.
Conclusions
Although protective role of PON1 against oxidative damage in vivo could be related to other activities, in our study arylesterase activity was useful to identify phenotypic differences with emphasis placed on two SNPs coding for nonconservative amino acid changes in the functional protein.</abstract><cop>London</cop><pub>Springer London</pub><pmid>30588556</pmid><doi>10.1007/s10067-018-4394-6</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6126-8786</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0770-3198 |
| ispartof | Clinical rheumatology, 2019-05, Vol.38 (5), p.1329-1337 |
| issn | 0770-3198 1434-9949 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2161065190 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Amino acid sequence Antioxidants - metabolism Arteriosclerosis Arthritis, Rheumatoid - complications Arthritis, Rheumatoid - enzymology Arthritis, Rheumatoid - genetics Aryldialkylphosphatase - genetics Aryldialkylphosphatase - metabolism Arylesterase Cardiovascular diseases Cardiovascular Diseases - enzymology Cardiovascular Diseases - etiology Cardiovascular Diseases - genetics Case-Control Studies Enzymatic activity Enzyme-linked immunosorbent assay Enzymes Female Genotype Genotyping Humans Male Medicine Medicine & Public Health Middle Aged Morbidity Original Article Paraoxonase Polymorphism, Single Nucleotide Rheumatoid arthritis Rheumatology Single-nucleotide polymorphism Spain |
| title | Functional implications of single nucleotide polymorphisms rs662 and rs854860 on the antioxidative activity of paraoxonase1 (PON1) in patients with rheumatoid arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T07%3A50%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Functional%20implications%20of%20single%20nucleotide%20polymorphisms%20rs662%20and%20rs854860%20on%20the%20antioxidative%20activity%20of%20paraoxonase1%20(PON1)%20in%20patients%20with%20rheumatoid%20arthritis&rft.jtitle=Clinical%20rheumatology&rft.au=Mucientes,%20Arkaitz&rft.date=2019-05-01&rft.volume=38&rft.issue=5&rft.spage=1329&rft.epage=1337&rft.pages=1329-1337&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-018-4394-6&rft_dat=%3Cproquest_cross%3E2160648693%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2160648693&rft_id=info:pmid/30588556&rfr_iscdi=true |